Literature DB >> 12403559

Cognitive deficits in neurofibromatosis 1.

Kathryn North1, Shelley Hyman, Belinda Barton.   

Abstract

Cognitive deficits and academic learning difficulties are the most common neurologic "complication" of neurofibromatosis 1 in childhood and can be responsible for significant lifetime morbidity. There is a slight increase in the frequency of mental retardation (Wechsler Full-Scale IQ < 70) in children with neurofibromatosis 1, but the mean Full-Scale IQ for the patient group is within 1 SD of the population mean. Academic difficulties are common, as are specific deficits in visuospatial ability, executive function, expressive and receptive language, and attentional skills. Behavioral and psychosocial problems have a major impact on quality of life, although there are few objective studies in this area Current research is focusing on the pathogenesis of the disorder. Clinical studies have identified possible radiologic and pathologic markers for cognitive deficits in neurofibromatosis 1, which can now be explored in animal models.

Entities:  

Mesh:

Year:  2002        PMID: 12403559     DOI: 10.1177/088307380201700811

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  21 in total

1.  Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.

Authors:  Sandra P Toelle; Andrea Poretti; Peter Weber; Tatjana Seute; Jacoline E C Bromberg; Ianina Scheer; Eugen Boltshauser
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

2.  Observations on intelligence and behavior in 15 patients with Legius syndrome.

Authors:  Ellen Denayer; Mie-Jef Descheemaeker; Douglas R Stewart; Kathelijn Keymolen; Ellen Plasschaert; Sarah L Ruppert; Joseph Snow; Audrey E Thurm; Lisa A Joseph; Jean-Pierre Fryns; Eric Legius
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

Review 3.  Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins.

Authors:  Xiaojing Ye; Thomas J Carew
Journal:  Neuron       Date:  2010-11-04       Impact factor: 17.173

4.  Clinical case rounds in child and adolescent psychiatry: neurofibromatosis type 1, cognitive impairment, and attention deficit hyperactivity disorder.

Authors:  Nicola Keyhan; Debbie Minden; Abel Ickowicz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2006-05

5.  Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).

Authors:  Lori Wiener; Haven Battles; Sima Zadeh Bedoya; Andrea Baldwin; Brigitte C Widemann; Maryland Pao
Journal:  J Genet Couns       Date:  2017-07-23       Impact factor: 2.537

6.  Absence of exon 17 c.2970-2872delAAT mutation in Turkish NF1 patients with mild phenotype.

Authors:  Yunus Kasim Terzi; Burcu Sirin; Esra Serdaroglu; Banu Anlar; Sabiha Aysun; Guzen Hosgor; Elif Acar Arslan; Sukriye Ayter
Journal:  Childs Nerv Syst       Date:  2011-07-06       Impact factor: 1.475

7.  Young adults' experience of living with neurofibromatosis type 1.

Authors:  Grete Hummelvoll; Kjell Magnus Antonsen
Journal:  J Genet Couns       Date:  2012-07-20       Impact factor: 2.537

8.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

9.  Reduced cerebral arterial spin-labeled perfusion in children with neurofibromatosis type 1.

Authors:  K W Yeom; R M Lober; P D Barnes; C J Campen
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

10.  Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.

Authors:  Lianne C Krab; Arja de Goede-Bolder; Femke K Aarsen; Saskia M F Pluijm; Marlies J Bouman; Jos N van der Geest; Maarten Lequin; Coriene E Catsman; Willem Frans M Arts; Steven A Kushner; Alcino J Silva; Chris I de Zeeuw; Henriëtte A Moll; Ype Elgersma
Journal:  JAMA       Date:  2008-07-16       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.